NCT04392960 2026-04-16
Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis
Fondazione IRCCS Policlinico San Matteo di Pavia
Phase NA Completed
Clinical Trials
13 trialsNCT04839003 2026-04-16
ReAL
Fondazione IRCCS Policlinico San Matteo di Pavia
Recruiting
NCT06205953 2026-04-16
EUREKA
Fondazione IRCCS Policlinico San Matteo di Pavia
Recruiting
NCT06383143 2026-04-16
ProDigALIty
Fondazione IRCCS Policlinico San Matteo di Pavia
Recruiting
NCT04847453 2026-04-13
Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT07524634 2026-04-13
Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) Amyloidosis
Case Comprehensive Cancer Center
Phase 2 Not yet recruiting
NCT04512235 2026-04-07
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)
Alexion Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT05898646 2026-03-30
Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial
Mayo Clinic
Phase 2 Recruiting
NCT06971848 2026-03-30
ETCABIO
University Hospital, Angers
Phase NA Not yet recruiting
NCT05444920 2026-03-27
ITA-WebNet
Fondazione IRCCS Policlinico San Matteo di Pavia
Recruiting
NCT07081646 2026-03-24
ALACRITY
Alexion Pharmaceuticals, Inc.
Phase 1/2 Recruiting
NCT07250269 2026-03-24
Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis
Gracell Biotechnologies (Shanghai) Co., Ltd.
Phase 1 Recruiting
NCT01408225 2026-03-23
B-SCR-MM
Ohio State University Comprehensive Cancer Center
Recruiting